In the model of cisplatin-induced cognitive dysfunction, we showed that treatment with a different HDAC6 inhibitor (ACY-1215) that is not brain penetrant was sufficient to reverse cisplatin-induced peripheral neuropathy but not cisplatin-induced cognitive dysfunction 18. This evidence concerns the gene HDAC6 and peripheral neuropathy.